AVITA Medical, Inc. RCEL
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- +353.62%
- 1 year
- +326.43%
- Open
- 16.54
- Prev close
- 16.71
- Mkt cap
- 484.01M
- Vol
- 597.05K
- Avg vol
- 482.35K
- EPS
- -1.43
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 15.24
- High
- 16.60
- Forward P/E
- -14.33
- Beta
- 1.54
- Short ratio
- 10.24
- Inst. own
- 23.45%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 11.87
- 200-d avg
- 10.61
- 1y target
- 16.81
News
1 week ago globenewswire.com
AVITA Medical to Announce Third Quarter 2026 Financial Results
VALENCIA, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (“AVITA Medical,” or the “Company”), a leading therapeutic acute wound care company delivering…
-
2 weeks ago benzinga.com
BTIG Maintains Buy on AVITA Medical, Raises Price Target to $15
BTIG analyst Ryan Zimmerman maintains AVITA Medical (NASDAQ:RCEL) with a Buy and raises the price target from $11 to $15.
2 weeks ago benzinga.com
AVITA Medical Q2 2026 Earnings Call Transcript
On Thursday, AVITA Medical (NASDAQ:RCEL) discussed second-quarter financial results during its earnings call. The full transcript is provided below. Benzinga APIs provide real-time access to earnings…
2 weeks ago defenseworld.net
Head-To-Head Comparison: Organigram Global (NASDAQ:OGI) versus Avita Medical (NASDAQ:RCEL)
Organigram Global (NASDAQ: OGI - Get Free Report) and Avita Medical (NASDAQ: RCEL - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two…
3 weeks ago seekingalpha.com
Leading Indicators For The October Breakout Cycle
Q4 historically delivers outsized S&P 500 returns, especially following midterm election years, supporting the 'October breakout cycle' thesis. Since 2000, the gains in the fourth quarter have…
4 weeks ago gurufocus.com
Is AVITA Medical Inc (RCEL) Overvalued After 5.9% Rally? GF Value Says Overvalued
On October 02, 2026, AVITA Medical Inc (RCEL) shares rose 5.9% to a current price of $12.72, within a 52-week range of $3.22 to $12.76. The stock has shown impr
1 month ago defenseworld.net
NewEdge Advisors LLC Purchases 62,046 Shares of Avita Medical Inc. $RCEL
NewEdge Advisors LLC grew its position in Avita Medical Inc. (NASDAQ: RCEL) by 71.4% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned…
1 month ago seekingalpha.com
AVITA Medical, Inc. (RCEL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
AVITA Medical, Inc. (RCEL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
1 month ago globenewswire.com
AVITA Medical to Participate in Lake Street Best Ideas Growth Conference and Morgan Stanley Healthcare Conference
VALENCIA, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today announced…
2 months ago zacks.com
All You Need to Know About Avita Medical (RCEL) Rating Upgrade to Buy
Avita Medical (RCEL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
2 months ago zacks.com
Avita Medical Inc. (RCEL) is a Great Momentum Stock: Should You Buy?
Does Avita Medical Inc. (RCEL) have what it takes to be a top stock pick for momentum investors? Let's find out.
2 months ago seekingalpha.com
AVITA Medical: Favorable Reimbursements For Skin Wound Care
AVITA Medical's reimbursement is now becoming more predictable. I believe this removes one of their main adoption barriers going forward. The RECELL GO international rollout and PermeaDerm's positive…
-
2 months ago benzinga.com
TD Cowen Maintains Buy on AVITA Medical, Raises Price Target to $14
TD Cowen analyst Joshua Jennings maintains AVITA Medical (NASDAQ:RCEL) with a Buy and raises the price target from $12 to $14.
-
2 months ago benzinga.com
BTIG Maintains Buy on AVITA Medical, Raises Price Target to $11
BTIG analyst Ryan Zimmerman maintains AVITA Medical (NASDAQ:RCEL) with a Buy and raises the price target from $7 to $11.
2 months ago marketbeat.com
Avita Medical PermeaDerm Study Shows 70% Cost Reduction vs. Allograft
Avita Medical NASDAQ: RCEL presented results from its PermeaDerm-I study, a randomized controlled trial evaluating PermeaDerm as temporary wound coverage following excision and before split-thickness…
2 months ago seekingalpha.com
AVITA Medical, Inc. (RCEL) Shareholder/Analyst Call Transcript
AVITA Medical, Inc. (RCEL) Shareholder/Analyst Call Transcript
-
2 months ago benzinga.com
AVITA Medical Announces PermeaDerm-I Study Met Primary Endpoint, Delivering Clinically Comparable Outcomes To Cadaveric Allograft With 70% Cost Reduction
Primary endpoint achieved, demonstrating a 70% economic advantage over allograft based on product cost per percent total body surface area treated (p<0.001) 96% reduction in preparation time and…
2 months ago globenewswire.com
AVITA Medical Announces Positive PermeaDerm® Study Results Demonstrating 70% Economic Advantage over Allograft and Comparable Clinical Outcomes
AVITA Medical's PermeaDerm study shows 70% lower product cost than allograft, with comparable clinical outcomes and a 96% reduction in preparation time.
2 months ago marketbeat.com
Avita Medical Raises 2026 Revenue Outlook as Q2 Sales Climb 18%
Avita Medical NASDAQ: RCEL reported second-quarter 2026 revenue of $21.7 million, up 13% sequentially from $19.3 million in the first quarter and 18% from $18.4 million a year earlier, as the…
2 months ago marketbeat.com
Avita Medical Targets Q4 2025 Cash Flow Breakeven as Revenue Growth Builds
Avita Medical NASDAQ: RCEL expects continued sequential revenue growth and aims to reach cash flow breakeven in the fourth quarter of 2025, President and CEO Cary Vance said at the Canaccord 46th…
2 months ago seekingalpha.com
AVITA Medical, Inc. (RCEL) Shareholder/Analyst Call Transcript
AVITA Medical, Inc. (RCEL) Shareholder/Analyst Call Transcript
2 months ago globenewswire.com
AVITA Medical to Host Investor Webinar Briefing
VALENCIA, Calif., Aug. 09, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, invites…
2 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers AVITA Medical (NASDAQ:RCEL) stock rose 58.4% to $7.53 during Friday's regular session. The company's market cap stands at $146.1 million. As per the press release, Q2 earnings came out…
2 months ago globenewswire.com
AVITA Medical Announces Participation at Canaccord Genuity Growth Conference
VALENCIA, Calif., Aug. 07, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today announced…
-
2 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Doximity (NYSE:DOCS) stock rose 85.1% to $38.25 during Friday's pre-market session. The market value of their outstanding shares is at $3.7 billion. As per the news, the Q1 earnings report…
2 months ago benzinga.com
This SpaceX Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday
Wall Street analysts upgraded AVITA, Etsy, Unity, and raised target prices for these stocks. See what others think before buying Unity.
-
2 months ago benzinga.com
BTIG Upgrades AVITA Medical to Buy, Announces $7 Price Target
BTIG analyst Ryan Zimmerman upgrades AVITA Medical (NASDAQ:RCEL) from Neutral to Buy and announces $7 price target.
2 months ago marketbeat.com
Avita Medical Q2 Earnings Call Highlights
Avita Medical NASDAQ: RCEL reported second-quarter 2026 revenue of $21.7 million, up 18% from a year earlier and 13% sequentially, as growth in its RECELL wound-care product and newer portfolio…
2 months ago seekingalpha.com
AVITA Medical, Inc. (RCEL) Q2 2026 Earnings Call Transcript
AVITA Medical, Inc. (RCEL) Q2 2026 Earnings Call Transcript
2 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Doximity (NYSE:DOCS) stock increased by 65.6% to $34.22 during Thursday's after-market session. The market value of their outstanding shares is at $3.8 billion. The company's, Q1 earnings…
-
2 months ago benzinga.com
AVITA Medical Raises FY2026 Sales Guidance from $80.000M-$85.000M to $86.000M-$89.000M vs $82.350M Est
AVITA Medical (NASDAQ:RCEL) raises FY2026 sales outlook from $80.000 million-$85.000 million to $86.000 million-$89.000 million vs $82.350 million estimate.
-
2 months ago benzinga.com
AVITA Medical Q2 EPS $(0.25) Beats $(0.29) Estimate, Sales $21.702M Beat $20.167M Estimate
AVITA Medical (NASDAQ:RCEL) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.29) by 13.79 percent. This is a 34.21 percent increase over losses of…
3 months ago benzinga.com
Why Celestica Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket
Celestica Inc (NYSE: CLS) exceeded analyst estimates with quarterly earnings of $2.54 per share and revenue of $4.7 billion, leading to a 4.7% jump in pre-market trading. Other top gainers include…
3 months ago benzinga.com
Why ServiceNow Shares Are Trading Higher By 7%; Here Are 20 Stocks Moving Premarket
ServiceNow Inc (NOW) rose in pre-market trading after reporting better-than-expected Q2 results. LGCL, PLAG, EHGO, ZYBT, DOMO, AEHL, HYLN, LBGJ, RYAM gained. LESL, ZCMD, WHLR fell.
-
3 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers AVITA Medical (NASDAQ:RCEL) stock moved upwards by 11.1% to $4.9 during Thursday's after-market session. The market value of their outstanding shares is at $143.1 million. Lisata Therapeutics…
-
5 months ago benzinga.com
Lake Street Upgrades AVITA Medical to Buy, Raises Price Target to $6
Lake Street analyst Frank Takkinen upgrades AVITA Medical (NASDAQ:RCEL) from Hold to Buy and raises the price target from $3.5 to $6.
-
5 months ago benzinga.com
AVITA Medical Reports Q1 2026 Results: Full Earnings Call Transcript
AVITA Medical Reports Q1 2026 Results: Full Earnings Call Transcript
-
5 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Thursday's After-Market Session
-
5 months ago benzinga.com
AVITA Medical Affirms FY2026 Sales Guidance of $80.000M-$85.000M vs $82.258M Est
AVITA Medical (NASDAQ:RCEL) affirms FY2026 sales outlook from $80.000 million-$85.000 million to $80.000 million-$85.000 million vs $82.258 million estimate.
-
5 months ago benzinga.com
AVITA Medical Q1 EPS $(0.35) Misses $(0.28) Estimate, Sales $19.251M Beat $18.175M Estimate
AVITA Medical (NASDAQ:RCEL) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of $(0.28) by 25 percent. This is a 33.96 percent increase over losses of…
-
6 months ago benzinga.com
AVITA Medical Appoints Cary Vance President, CEO; Jan Stern As Board Chair, Effective Immediately
AVITA Medical®, Inc. (NASDAQ:RCEL, ASX: AVH)), a leading therapeutic acute wound care company, today announced that its Board of Directors has appointed Cary Vance as President and Chief Executive…
-
6 months ago benzinga.com
AVITA Medical Announces Data From Cohealyx-I Multi-Center Trial Shows Reduction Of ~20 Days In Mean Time To Skin Grafting For Participants With Full-Thickness Wounds
AVITA Medical®, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company, today announced positive interim results from its Cohealyx-I multi-center study demonstrating a…
-
6 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session
-
6 months ago benzinga.com
AVITA Medical Enters Into 10-Yr Agreement With BARDA Valued At Up To $25.5M To Strengthen National Preparedness For Burn Mass Casualty Incidents
Agreement ensures rapid nationwide access to RECELL® for burn mass casualty incidents, providing BARDA access to 3,000 units any time over the 10-year contract VALENCIA, Calif., April 08, 2026 (GLOBE…
-
8 months ago benzinga.com
Northland Capital Markets Initiates Coverage On AVITA Medical with Outperform Rating, Announces Price Target of $10
Northland Capital Markets analyst Carl Byrnes initiates coverage on AVITA Medical (NASDAQ:RCEL) with a Outperform rating and announces Price Target of $10.
-
8 months ago benzinga.com
D. Boral Capital Maintains Buy on AVITA Medical, Maintains $10 Price Target
D. Boral Capital analyst Jason Kolbert maintains AVITA Medical (NASDAQ:RCEL) with a Buy and maintains $10 price target.
-
8 months ago benzinga.com
AVITA Medical Affirms FY2026 Sales Guidance of $80.000M-$85.000M vs $85.600M Est
AVITA Medical (NASDAQ:RCEL) affirms FY2026 sales outlook from $80.000 million-$85.000 million to $80.000 million-$85.000 million vs $85.600 million estimate.
8 months ago benzinga.com
AVITA Medical Q4 Earnings Summary & Key Takeaways
AVITA Medical Q4 Earnings Summary & Key Takeaways
-
8 months ago benzinga.com
AVITA Medical Q4 EPS $(0.38) Misses $(0.36) Estimate, Sales $17.616M Miss $17.838M Estimate
AVITA Medical (NASDAQ:RCEL) reported quarterly losses of $(0.38) per share which missed the analyst consensus estimate of $(0.36) by 4.4 percent. This is a 13.64 percent increase over losses of…